About Immunovia AB (publ) 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

Press release

Background and reason 

Immunovia’s mission is to increase survival rates for patients with pancreatic cancer by detecting the cancer at stage 1 or 2. Immunovia is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. Pancreatic cancer is a very lethal cancer with a low survival rate.  The low survival rate is explained by the fact that pancreatic cancer is usually detected at a late stage when the tumor has metastasized and surgery is no longer an option. Pancreatic cancer is the third leading cause of cancer deaths in Europe and the United States.  

Immunovia plans to introduce its next-generation test to the market in 2025. The U.S. will be the first market targeted for commercialization. The Company has made significant progress in developing the test in 2023. By restructuring and streamlining its operations, Immunovia has accelerated research and development progress, as confirmed by the successful completion of the discovery phase for the next-generation test. This discovery represents a significant breakthrough and marks an important milestone in the Company’s quest for early detection of pancreatic cancer. 

During 2024, Immunovia will focus on finalizing the development of the new test, proving its value through clinical studies and securing the resources and commercial partnerships required for a successful market launch in 2025.  

Website: https://investor.immunovia.com/ 

 

Rights Issue

 

 

SEK 70 million 

May 2024

Financial Adviser